MANHATTAN ASSOCIATES INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MANHATTAN ASSOCIATES INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $131.30M | Feb 5, 2016 |
| FY2015 | Dec 31, 2014 | $134.60M | Feb 5, 2016 |
| FY2015 | Dec 31, 2013 | $110.80M | Feb 5, 2016 |
| FY2014 | Dec 31, 2012 | $104.40M | Feb 5, 2015 |
| FY2013 | Dec 31, 2011 | $90.70M | Feb 6, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.08B | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $1.04B | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $928.73M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $767.08M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $663.64M | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | $147.08M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $149.76M | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $135.63M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $153.90M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $152.93M | Feb 5, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $144.09M | Feb 9, 2018 |
| FY2017 | Sep 30, 2017 | $152.88M | Feb 9, 2018 |
| FY2017 | Jun 30, 2017 | $154.14M | Feb 9, 2018 |
| FY2017 | Mar 31, 2017 | $143.49M | Feb 9, 2018 |
| FY2017 | Dec 31, 2016 | $147.59M | Feb 9, 2018 |
| FY2017 | Sep 30, 2016 | $152.21M | Feb 9, 2018 |
| FY2017 | Jun 30, 2016 | $154.89M | Feb 9, 2018 |
| FY2017 | Mar 31, 2016 | $149.86M | Feb 9, 2018 |
| FY2016 | Dec 31, 2015 | $141.44M | Feb 3, 2017 |
| FY2016 | Sep 30, 2015 | $142.30M | Feb 3, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.95M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $218.36M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $176.57M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $128.96M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $110.47M | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | $20.54M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $24.97M | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $19.20M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $22.53M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $16.76M | Feb 5, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $279.80M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $261.60M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $209.88M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $152.70M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $134.33M | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | $28.20M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $34.98M | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $26.69M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $24.20M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $25.07M | Feb 5, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $145.06M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $137.69M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $126.81M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $111.88M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $97.63M | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | $20.56M | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | $20.45M | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | $19.93M | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | $23.33M | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | $21.78M | Feb 5, 2021 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $389.47M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $295.00M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $246.22M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $179.63M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $185.18M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $140.89M | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $146.91M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $137.35M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $164.07M | Feb 10, 2020 |
| FY2018 | Dec 31, 2016 | $139.35M | Feb 8, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.46M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $8.68M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $4.73M | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | $6.59M | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | $4.02M | Feb 6, 2024 |
| FY2022 | Dec 31, 2020 | $2.73M | Feb 6, 2023 |
| FY2021 | Dec 31, 2019 | $15.19M | Feb 7, 2022 |
| FY2020 | Dec 31, 2018 | $7.31M | Feb 5, 2021 |
| FY2019 | Dec 31, 2017 | $6.20M | Feb 10, 2020 |
| FY2018 | Dec 31, 2016 | $6.84M | Feb 8, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $839.39M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $757.55M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $673.35M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $570.18M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $539.71M | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $465.41M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $372.28M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $307.15M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $315.00M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $297.14M | Feb 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $314.77M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $299.13M | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | $278.28M | Feb 4, 2026 |
| FY2025 | Dec 31, 2022 | $226.80M | Feb 4, 2026 |
| FY2024 | Dec 31, 2021 | $250.64M | Feb 7, 2025 |
| FY2023 | Dec 31, 2020 | $218.90M | Feb 6, 2024 |
| FY2022 | Dec 31, 2019 | $142.28M | Feb 6, 2023 |
| FY2021 | Dec 31, 2018 | $147.15M | Feb 7, 2022 |
| FY2020 | Dec 31, 2017 | $174.96M | Feb 5, 2021 |
| FY2019 | Dec 31, 2016 | $169.37M | Feb 10, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $62.24M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $62.23M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $62.24M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $62.23M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $62.24M | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $62.25M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $62.24M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $62.24M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $62.25M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $62.23M | Feb 9, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $345.10M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $329.44M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $304.70M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $253.71M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $269.84M | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $236.52M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $159.49M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $163.36M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $186.12M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | $184.56M | Feb 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $328.75M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | $266.23M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | $270.74M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | $225.46M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | $263.71M | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | $204.71M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | $110.68M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | $99.13M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | $125.52M | Feb 8, 2019 |
| FY2018 | Dec 31, 2016 | $95.62M | Feb 8, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 4, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 4, 2026 |
| FY2024 | Dec 31, 2022 | 2 | Feb 7, 2025 |
| FY2023 | Dec 31, 2021 | 1 | Feb 6, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 5, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 5, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 59.85M | Feb 4, 2026 |
| FY2025 | Dec 31, 2024 | 60.92M | Feb 4, 2026 |
| FY2024 | Dec 31, 2023 | 61.57M | Feb 7, 2025 |
| FY2023 | Dec 31, 2022 | 62.19M | Feb 6, 2024 |
| FY2022 | Dec 31, 2021 | 63.15M | Feb 6, 2023 |
| FY2021 | Dec 31, 2020 | 63.53M | Feb 7, 2022 |
| FY2020 | Dec 31, 2019 | 63.46M | Feb 5, 2021 |
| FY2019 | Dec 31, 2018 | 64.86M | Feb 10, 2020 |
| FY2018 | Dec 31, 2017 | 67.78M | Feb 8, 2019 |
| FY2017 | Dec 31, 2016 | 70.23M | Feb 9, 2018 |